Skip to Content

Posts tagged with "Drug Industry History"

  • Business and Markets

    GSK’s Getting Better. Just Ask the CEO.

    There are some interesting statements from GlaxoSmithKline CEO Andrew Witty here at Reuters. He admits that morale was completely in the scupper around the place a few months ago, which certainly seems to be true, but says that they’re turning things around. To that point, remember all that stuff a few years ago about how… Read More
  • Drug Development

    The View From Pfizer’s Corner Offices

    There’s a good article from Lee Howard up at The Day (the New London/Groton newspaper) on the changes going on at Pfizer. It’s the story according to management, though, which is worth having for its compare-and-contrast uses: Despite the looming uncertainty, according to company spokesmen, the new research structure has added energy an… Read More
  • Business and Markets

    CafePharma Will Now Approach The Bench

    Here’s an interesting situation for you: according to IguanaBio, a shareholder lawsuit over the failed Vytorin ENHANCE clinical trial (that’s caused Schering-Plough and Merck so much grief) is going to use posts on CafePharma as evidence. That will be worth watching. CafePharma’s message boards have been described (accurately, I&# Read More
  • Business and Markets

    Akt and Mek, But Not PDQ

    Well, the ASCO meeting has been roaring along, with dozens of press releases coming out. (Go to Google News and type that acronym in if you want to get the full experience). They range from the pretty-interesting to the despair-inducing, but one bit of news struck me as particularly worth noting. That’s the early-stage deal… Read More
  • Drug Development

    The NIH Takes the Plunge

    The NIH has announced that they’re going to start up a preclinical drug discovery effort to address rare diseases. I find this interesting for several reasons. For one thing, it’s worth a try for conditions where no company has seen a way to fund research, and there are quite a few of them. Treating rare… Read More
  • Business and Markets

    San Francisco Biotech: Holding Up, or Not?

    I’ve got a piece coming up today at The Atlantic Monthly‘s business site on the state of the biotech industry out in the Bay Area. Since the Genentech takeover fight broke out, a persistent theme in the comments here (and in e-mail that I’ve received) has been how well the industry is holding up out… Read More
  • Drug Industry History

    Book Review Department

    For those who are interested, I have a review up at Nature Biotechnology of Reasonable Rx: Solving the Drug Price Crisis, a book that proposes an. . .interesting solution for reworking the drug industry. And as Fate would have it, I also have a review in the latest issue of Nature Chemistry of Drug Truths: Read More
  • Cardiovascular Disease

    Farewell to ACAT, and to Lots of Time and Money, Too

    Back when I joined the first drug company I ever worked for, the group in the lab next door was working on an enzyme called ACAT, acyl CoA:cholesterol acyltranferase. It’s the main producer of cholesterol esters in cells, and is especially known to be active in the production of foam cells in atherosclerosis. It had… Read More
  • Biological News

    Genes to Diseases: Hard Work, You Say?

    So I see that the headlines are that it’s proving difficult to relate gene sequences to specific diseases. (Here’s the NEJM, free full-text). I can tell you that the reaction around the drug industry to this news is a weary roll of the eyes and a muttered “Ya don’t say. . .” That’s because we… Read More
  • Drug Industry History

    Who They?

    I try to keep up with the drug-industry news in general, so once in a while I just hop over to Google News and type “pharmaceutical” into the search box. That generally gets me a barrage of press releases, lucky me, and this morning was no different. But what struck me was that basically the… Read More